130953-92-3

Upstream product

• 130933-46-9 4-<4-(4-fluorophenyl)-1-piperazinyl>butyric acid 
• 130933-38-9 (6aR^*,10aR^*,11R^*)-11-amino-2-chloro-6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin 
• 130933-88-9 ethyl 4-<4-(4-fluorophenyl)-1-piperazinyl>butyrate 
• 2252-63-3 1-(4-Fluorophenyl)piperazine 
• 130933-34-5 (6aR^*,10aR^*,11R^*)-2-chloro-11-(formylamino)-6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin 
• 130933-30-1 (4aR,11aR)-7-Chloro-2,3,4,4a,11,11a-hexahydro-1H-10-thia-dibenzo[a,d]cyclohepten-5-one 

Relevant academic research and scientific papers

A New Class of Calcium Antagonists. Synthesis and Biological Activity of 11--6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin Derivatives

A series of 11--6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin derivatives were prepared and found to be structurally new class of calcium antagonists.The structure-activivty relationship studies indicated that the optimum was (6aR*,10aR*,11R*)-11-butyryl>amino>-6,6a,7,8,9,10,10a,11-octahydrodibenzothiepin (31, pA2 8.16), which was superior to diltiazem (pA2 7.42) in calcium antagonistic activity.Compound 31 showed antihypertensive activity in anesthetized rats, without a significant effect on the heart rate.It had also antianginal effects in vasopressin-induced ST-elevation testings in rats.These potencies of 31 were essentially equal to those of diltiazem.